{{위키데이터 속성 추적}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 418858405
| IUPAC_name = 2-Methyl-4-(4-methyl-1-piperazinyl)-10''H''-thieno[2,3-''b''][1,5]benzodiazepine
| image = Olanzapine.svg
| width = 200px
| image2 = Olanzapine-from-xtal-3D-balls.png
| width2 = 225px
<!--Clinical data-->
| tradename = Zyprexa, others<ref name=Drugnames/>
| Drugs.com = {{drugs.com|monograph|olanzapine}}
| MedlinePlus = a601213
| licence_US = Olanzapine
| pregnancy_AU = C
| pregnancy_US = C
| licence_EU = yes
| legal_AU = S4
| legal_CA = Rx-only
| legal_US = Rx-only
| legal_NZ_comment = Prescription medicine
| legal_UK = POM
| routes_of_administration = [[Oral administration|By mouth]], [[intramuscular injection]]
<!--Pharmacokinetic data-->
| bioavailability = 60-65%<ref>{{서적 인용| last1 = Kassahun| first1 = Kelem| last2 = Mattiuz| first2 = Edward | last3 = Nyhart|first3 = Eldon | name-list-format = vanc | title = DISPOSITION AND BIOTRANSFORMATION OF THE ANTIPSYCHOTIC AGENT OLANZAPINE IN HUMANS | publisher = Drug Metabolism and Disposition | date = January 1, 1997| location = | page = 81 | url = http://dmd.aspetjournals.org/content/25/1/81.long | doi = | id = | isbn = }}</ref><ref>{{저널 인용| vauthors= Callaghan JT, Bergstrom RF, Ptak LR, et al| title = Olanzapine: pharmacokinetic and pharmacodynamic profile. | journal = Clin Pharmacokinetics| volume = 37 | issue = 3 | pages = 177–193 | date = September 1999 | pmid = 10511917| doi = 10.2165/00003088-199937030-00001 }}</ref><ref>{{저널 인용| vauthors = Mauri MC, Volonteri LS, Colasanti A, et al| title = Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. | journal = Clinical Pharmacokinetics | volume = 46 | issue = 5 | pages = 359–88 | date = 2007 | pmid = 17465637| doi = 10.2165/00003088-200746050-00001 }}</ref>
| protein_bound = 93%<ref name="TGA">{{웹 인용|title=PRODUCT INFORMATION OLANZAPINE SANDOZ® 2.5mg/5mg/7.5mg/10mg/15mg/20mg FILM-COATED TABLETS |work=TGA eBusiness Services|publisher=Sandoz Pty Ltd|date=8 June 2012|accessdate=26 November 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02375-3|format=PDF}}</ref>
| metabolism = Liver (direct glucuronidation and [[CYP1A2]] mediated oxidation)
| elimination_half-life = 33 hours, 51.8 hours (elderly)<ref name = TGA/>
| excretion = Urine (57%; 7% as unchanged drug), faeces (30%)<ref name = TGA/><ref name="MSR">{{웹 인용|title=Zyprexa, Zyprexa Relprevv (olanzapine) dosing, indications, interactions, adverse effects, and more|accessdate=26 November 2013|work=Medscape Reference|publisher=WebMD|url=http://reference.medscape.com/drug/zyprexa-relprevv-olanzapine-342979#showall}}</ref>
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 132539-06-1
| ATC_prefix = N05
| ATC_suffix = AH03
| PubChem = 4585
| IUPHAR_ligand = 47
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00334
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10442212
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = N7U69T4SZR
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00454
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 7735
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 715
<!--Chemical data-->
| C=17 | H=20 | N=4 | S=1
| molecular_weight = 312.439
| smiles = CN1CCN(CC1)C/2=N/c4ccccc4Nc3sc(C)cc\23
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KVWDHTXUZHCGIO-UHFFFAOYSA-N
| melting_point = 195
| solubility = Practically insoluble in water
}}
'''올란자핀'''(Olanzapine)은(상품명으로 '자이프렉사' 등이 사용된다) 미국 [[일라이 릴리 앤드 컴퍼니]]가 [[1996년]]에 개발 및 출시하여 [[조현병]], [[조울증]]에 사용되는 [[비정형적 항정신병제제]]이므로, 대한민국에서는 물질 및 용도 특허 만료 이후에, 자이레핀([[환인제약]]), 뉴로자핀([[명인제약]]) 등 동일 성분의 [[제네릭 의약품]]으로 많이 보급되어 있다.

== 효능 및 효과 ==
도파민 D2 수용체와 세로토닌 5-HT2 수용체에 대한 길항 작용을 통해서 항정신병 작용을 나타내는 조현병 치료제로, 도파민 및 세로토닌 수용체에 대한 높은 친화성을 가지고 있다.

== 적응증 ==
* [[조현병]]
* [[양극성 장애]]

== 각주 ==
{{각주}}

{{항정신병제제}}
{{전거 통제}}
{{토막글|의학}}

[[분류:도파민 대항제]]
[[분류:비정형적 항정신병제제]]
[[분류:피페라진]]
[[분류:식욕촉진제]]
[[분류:기분 안정제]]
[[분류:알파-1 차단제]]
[[분류:알파-2 차단제]]
[[분류:5-HT2A 대항제]]
[[분류:5-HT2B 대항제]]
[[분류:5-HT2C 대항제]]
[[분류:5-HT6 대항제]]
[[분류:5-HT7 대항제]]
[[분류:D1 대항제]]
[[분류:D2 대항제]]
[[분류:D3 대항제]]
[[분류:D4 대항제]]
[[분류:D5 대항제]]